Cargando…

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them and do not have an alternative drug to overcome the problem. The levels of β-cate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sang-Kyu, Cho, Yong-Hee, Cha, Pu-Hyeon, Yoon, Jeong-Soo, Ro, Eun Ji, Jeong, Woo-Jeong, Park, Jieun, Kim, Hyuntae, Il Kim, Tae, Min, Do Sik, Han, Gyoonhee, Choi, Kang-Yell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244225/ https://www.ncbi.nlm.nih.gov/pubmed/30459318 http://dx.doi.org/10.1038/s12276-018-0182-2

Ejemplares similares

A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
por: Park, Jieun, et al.
Publicado: (2019)

KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer
por: Cho, Yong-Hee, et al.
Publicado: (2016)

Euodia sutchuenensis Dode extract stimulates osteoblast differentiation via Wnt/β-catenin pathway activation
por: Hwang, Jeong-Ha, et al.
Publicado: (2015)

WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation
por: Jeong, Woo-Jeong, et al.
Publicado: (2019)

Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway
por: Jeong, Woo-Jeong, et al.
Publicado: (2018)

WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer
por: Ro, Eun Ji, et al.
Publicado: (2019)

Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer
por: Cha, Pu-Hyeon, et al.
Publicado: (2016)

Stabilization of Sur8 via PKCα/δ degradation promotes transformation and migration of colorectal cancer cells
por: Lee, Kug Hwa, et al.
Publicado: (2017)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer
por: Ryu, Won-Ji, et al.
Publicado: (2020)

K-Ras stabilization by estrogen via PKCδ is involved in endometrial tumorigenesis
por: Koo, Kyoung-Hwa, et al.
Publicado: (2015)

APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer
por: Cha, Pu-Hyeon, et al.
Publicado: (2020)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer
por: Park, Hye-Jin, et al.
Publicado: (2017)

Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells
por: Cho, Yong-Hee, et al.
Publicado: (2020)

Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling
por: Shin, Wookjin, et al.
Publicado: (2018)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis
por: Kwon, Ok-Seon, et al.
Publicado: (2020)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth
por: Choi, Sehee, et al.
Publicado: (2019)

Single particle tracking-based reaction progress kinetic analysis reveals a series of molecular mechanisms of cetuximab-induced EGFR processes in a single living cell
por: Kim, Do-Hyeon, et al.
Publicado: (2017)

Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway
por: Seo, HeeJung, et al.
Publicado: (2018)

KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas
por: Kim, Jeong-Oh, et al.
Publicado: (2015)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
por: Choi, Hee-Jeong, et al.
Publicado: (2023)

Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling
por: Kaduwal, Saluja, et al.
Publicado: (2015)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis
por: Valverde, Araceli, et al.
Publicado: (2017)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Han, Yu Na, et al.
Publicado: (2022)

A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS
por: Ryu, Won-Ji, et al.
Publicado: (2019)

Hovenia dulcis Thunb Extract and Its Ingredient Methyl Vanillate Activate Wnt/β-Catenin Pathway and Increase Bone Mass in Growing or Ovariectomized Mice
por: Cha, Pu-Hyeon, et al.
Publicado: (2014)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
por: Liang, Samantha I., et al.
Publicado: (2018)

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles
por: Strand, Matthew S., et al.
Publicado: (2019)

Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients
por: Kim, Yoonjung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1o5ivjscgjb6ijsu9ro1iocskp